Mount Yale Investment Advisors LLC Sells 1,651 Shares of Edwards Lifesciences Co. (NYSE:EW)

Mount Yale Investment Advisors LLC cut its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 20.1% during the 1st quarter, Holdings Channel.com reports. The fund owned 6,569 shares of the medical research company’s stock after selling 1,651 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Edwards Lifesciences were worth $628,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Edwards Lifesciences by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock valued at $5,061,277,000 after buying an additional 600,994 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Edwards Lifesciences by 9.5% during the first quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company’s stock worth $1,813,089,000 after purchasing an additional 1,644,869 shares during the period. Brown Advisory Inc. increased its stake in shares of Edwards Lifesciences by 20.1% in the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after purchasing an additional 3,048,274 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Edwards Lifesciences by 2.4% in the fourth quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock valued at $1,283,098,000 after purchasing an additional 393,109 shares during the period. Finally, Norges Bank purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $648,540,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Edwards Lifesciences

In related news, CEO Bernard J. Zovighian bought 580 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was acquired at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the purchase, the chief executive officer now owns 3,268 shares in the company, valued at $280,198.32. The acquisition was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Bernard J. Zovighian acquired 580 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The stock was bought at an average price of $85.74 per share, with a total value of $49,729.20. Following the completion of the acquisition, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total value of $1,212,624.00. Following the sale, the vice president now owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The disclosure for this sale can be found here. Insiders have sold a total of 73,849 shares of company stock worth $6,381,503 over the last quarter. Company insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on EW shares. Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday. TD Cowen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $100.00 to $70.00 in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, July 25th. Wells Fargo & Company lowered their price objective on shares of Edwards Lifesciences from $99.00 to $90.00 and set an “overweight” rating on the stock in a research report on Thursday, July 25th. Finally, Barclays cut their target price on shares of Edwards Lifesciences from $101.00 to $90.00 and set an “overweight” rating for the company in a research report on Friday. Fourteen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $82.10.

Edwards Lifesciences Trading Down 1.9 %

Shares of EW traded down $1.23 during trading hours on Tuesday, reaching $62.51. 1,138,211 shares of the company traded hands, compared to its average volume of 3,795,484. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a market capitalization of $37.67 billion, a price-to-earnings ratio of 27.47, a price-to-earnings-growth ratio of 2.33 and a beta of 1.11. The company’s fifty day moving average price is $87.45 and its two-hundred day moving average price is $86.91. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same period last year, the company posted $0.66 EPS. Edwards Lifesciences’s revenue was up 6.7% on a year-over-year basis. Equities research analysts predict that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.